Ryeqo significantly improved heavy menstrual bleeding1,2
MBL volume <80 mL AND ≥50% reduction from baseline (last 35 days of treatment)
†Women in the placebo→Ryeqo group had received 28 weeks of active Ryeqo treatment by Week 52. Adapted from Al-Hendy et al. 2021 and Al-Hendy et al. 2022.1,2
Menstrual blood loss reduced by 89.9% at week 522
Percentage change in MBL volume over 52 weeks
Adapted from Al-Hendy et al. 2022.2
Significantly more women achieved amenorrhoea‡ with Ryeqo vs placebo1,2
Achieving amenorrhoea‡
‡Amenorrhoea is defined as reported amenorrhoea, spotting, or negligible bleeding (MBL < 5 mL) with supporting eDiary compliance at 2 consecutive visits. Adapted from
Al-Hendy et al. 2021 and Al-Hendy et al. 2022.1,2
Ryeqo significantly reduced pain associated with UF vs placebo1
Maximum NRS score ≤1 during the 35 days before the last dose of study drug
Adapted from Al-Hendy et al. 2021.1
Ryeqo significantly reduced uterine volume vs placebo1,2
LS mean change in uterine volume
Adapted from Al-Hendy et al. 2021 and Al-Hendy et al. 2022.1,2
Ryeqo significantly improved anaemia vs placebo1,2
Improvement in anaemia#
#Hb ≤10.5 g/dL at baseline who achieved an increase of > 2 g/dL from baseline to Week 24. ^The percentages of participants with a response were calculated in the subgroup of participants with anaemia (Hb level ≤10.5 g per decilite) at baseline and who had Hb data reported at Week 24. Adapted from Al-Hendy et al. 2021 and Al-Hendy et al. 2022.1,2
Ryeqo increased haemoglobin levels vs placebo2
Percentage change in Hb from baseline to Week 52 in anaemia-evaluable population
Adapted from Al-Hendy et al. 2022.2
Error bars show 95% confidence intervals.
Abbreviations: Hb, haemoglobin; LS, least squares; MBL, menstrual blood loss; UF, uterine fibroids; W, week.
References
- Al-Hendy A et al. N Engl J Med. 2021;384:630–42 (including supplementary appendix).
- Al-Hendy A et al. Obstet Gynecol. 2022;140:920–30 (including supplementary appendix).